- by Emil Salazar
- February 21 2017
The market for nucleic acid tests (NAT) used in blood donation screening is constrained by stagnant or declining transfusion rates in the developed world. Achieving business growth is challenging even for the largest IVD players. Competitive displacement, in the form of contract wins with blood organizations, is the most prominent strategy for growth, but is reliant upon vendors’ responsiveness to new transfusion transmitted infection (TTI) threats.
Earnings season is here. Many diagnostic companies are reporting their results for 2016, and some are providing guidance on what they expect for 2017. As might be expected, results for the year 2016 vary greatly among different companies. Kalorama's IVD analysts look into the 2016 revenue report to get a sense of what this means for the coming year.
The CDC recently said this year's flu vaccine was 48% effective. Despite that being lower than half, that's a good number. And for the most part, good or bad effectiveness doesn't change the vaccine market. In this article, we indicate why.
Roche moves into the hematology market with a European product launch, new options come to market for prenatal and newborn screening, and the FDA approves the first commercial Zika test for whole blood samples. Also, scientists design a 1-cent lab-on-a-chip and evidence builds for the power of breath tests to detect a variety of diseases. These are among the top news stories in IVD.
- by Bruce Carlson
- February 13 2017
- wound care
Our most recent report, Advanced Wound Care Products, finds J&J, Hill-Rom and KCI leading the advanced wound care products market. That doesn't mean there isn't room for other competitors, however, as this article details.
Rare bipartisanship at the end of the Obama administration led to the passage of the 21st Century Cures Act championed by former Vice President Biden. The Act’s leading provision authorized $1.8 billion over 7 years for National Institutes of Health (NIH)-administered research into cancer. Also relevant to cancer therapeutics and diagnostics market development were the Act’s provisions for easing requirements and accelerating review of FDA submissions.
Drug prices are a popular target of politicians and advocacy groups and patients themselves. Bad actors such as Mylan have given the industry a poor image. Now President Trump joined the chorus of voices saying prices are too high. But what's involved in pricing? Could steps to reduce pricing lead to worse care?
A sleeper health trend, urgent care centers have been around since the 1970's. But now they are getting attention. They offer walk-in care, great hours, and a wide-range of services. From location growth to booming business, here's seven things to know about urgent care centers from Kalorama's newly-published report on these facilities.
This blog post discusses findings from Kalorama Information’s just-published market research report, The World Market for Molecular Diagnostics, 7th Edition (Infectious Disease, Cancer, NAT Blood Screening, Transplantation, Histology/Cytology, Inherited Diseases).
Clinical molecular diagnostics does not lack in targets. Dynamic expansion markets in point-of-care testing and cancer have headlined assay development efforts in recent years, but they are not the only major opportunities in molecular diagnostics.
- by Bruce Carlson
- January 25 2017
- next generation sequencing
Several companies are competing in the market and in the courtroom to market a diagnostic platform from nanopore technology. There are noted limitations such as data quality, but also progress. A review of the ongoing push for next-generation sequencing at the nano level.